"Engineered T cell Therapy for Pediatric Cancer"

Stephen Gottschalk, M.D.

Member, St. Jude Faculty
Chair, Department of Bone Marrow Transplantation & Cellular Therapy
Endowed Chair in Bone Marrow Transplantation & Cellular Therapy
St. Jude Children’s Research Hospital

LEARNING OBJECTIVES:
Upon completion of this activity, participants should be able to:

1. Discuss T cell therapy approaches for pediatric cancer
2. Explain current limitations of adoptive T cell therapy approaches for pediatric cancers
3. Describe genetic engineering approaches to improve effector function of T cells

Speaker Disclosure:
Dr. Gottschalk has disclosed that he is a consultant to TESSA Therapeutics, Tidal, Catamaran Bio, Sanofi, and Novartis and a DSMB Member (immatics). No one else in a position to control content has any financial relationships to disclose. Conflict of interest information for the CME Advisory Committee members can be found on the following website: https://cme.ufl.edu/disclosure/. All relevant financial relationships have been mitigated.

Accreditation: The University of Florida College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

Credit: The University of Florida College of Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™.

Section # 2099